LIFECORE BIOMEDICAL, INC. \DE\ — Form SCHEDULE 13D/A
Filed July 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
22NW Fund, LP (Seattle, WA) filed an amended Schedule 13D/A regarding its beneficial ownership stake in LifeCore Biomedical, Inc. (Chaska, MN) on July 2, 2026. The filing document does not display the specific shareholding percentage, dollar amounts, or details of what changed from the prior filing, as the HTML content is inaccessible in this submission.
Why this rating
Schedule 13D amendments are routine disclosure updates for investors crossing 5% thresholds. Without visible specifics on ownership % or changes, cannot assess materiality. Presumed standard filing absent disclosed material alterations.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.